newsfilter
← Latest News
Earnings Call Transcripts·

UBS Global Biopharma Conference - CARDIFF ONCOLOGY INC

  • Explicit Guidance:

    • Cash Runway: Current cash of ~$34 million (as of Q3) is sufficient to fund operations through the end of Q3 2027.
    • Phase 3 Trial Initiation: Targeting staged initiation of the Phase 3 trial (CARD004) in the first quarter of 2027, pending funding.
  • Business-Segment Outlook:

    • Metastatic Colorectal Cancer (mCRC): Aiming for a treatment paradigm shift in the first-line setting for RAS-mutated metastatic colorectal cancer (mCRC), a population constituting ~50% of all mCRC patients where no new innovation has occurred in 20 years.
    • Combination Strategy: The 30 mg Onvancitib + FOLFIRI + Bevacizumab regimen is selected as the optimal registrational dose; preliminary data shows ~70%+ overall response rate (ORR) vs. ~42% for standard of care, with patients remaining on treatment >21 months.
    • Chronic Myelomonocytic Leukemia (CMML): Observing compelling monotherapy signals (ORR ~40%) in relapsed/refractory CMML patients (50% harbor RAS pathway mutations) with expected updated data presentation at the December ASH meeting.
    • Pipeline Expansion: Pursuing development in Small Cell Lung Cancer (SCLC) based on early monotherapy signals; recently received orphan drug designation for both CMML and SCLC.
  • Market and Competitive Outlook:

    • Unmet Need: Targeting the large, underserved RAS-mutated mCRC population currently reliant on chemotherapy (FOLFIRI/FOLFOX) and Bevacizumab, which has offered no significant ORR improvement in 20 years.
    • Competitive Differentiation: Competitors are largely focusing on MSS populations (using PD-1/VEGF inhibitors) or rare KRAS G12C mutations; Cardiff's approach targets the broad Pan-RAS mutation spectrum.
    • Mechanism Synergy: Unique mechanism relies on synergy between Onvancitib (PLK1 inhibitor), Irinotecan (Topoisomerase I inhibitor), and Bevacizumab to block angiogenesis (HIF-1-alpha) and DNA repair, providing a distinct advantage over Oxaliplatin-based combinations.
  • Macro / Industry Outlook:

    • Regulatory Pathway: Leveraged recent FDA "Fast-Track" designation and End-of-Phase 2 meeting outcomes to design a Phase 3 trial capable of supporting both Accelerated Approval (based on ORR and durability) and Full Approval (based on Progression-Free Survival/PFS).
    • Regulatory Strategy: Expecting frequent interactions with the FDA due to Fast-Track status; maintaining alignment with European regulators regarding the Phase 3 design.
  • Strategic Initiatives:

    • Phase 3 Trial Design: Designing a randomized, controlled, adequately powered Phase 3 trial comparing Onvancitib 30mg + FOLFIRI + Bevacizumab vs. FOLFIRI + Bevacizumab alone, with prospective enrollment of all RAS mutation subtypes (NRAS, KRAS).
    • Manufacturing & Diagnostics: Completed regulatory interactions regarding manufacturing and companion diagnostic requirements to ensure readiness for trial launch.
    • Trial Execution Strategy: Selected a CRO and planning a "staged initiation" of the Phase 3 trial to optimize resource utilization and speed.
  • Risks and Headwinds to Outlook:

    • Funding Dependency: Phase 3 initiation is contingent upon securing necessary funding, though current cash provides a runway to late 2027.
    • Trial Duration/PFS: While Phase 3 is powered for PFS, the interim Phase 2 data was not powered for PFS; full PFS maturity and potential approval timelines depend on the speed of enrollment and data maturity.
    • Regulatory Uncertainty: Accelerated approval relies on the strength of ORR and durability data; full approval requires robust PFS data, subject to standard regulatory validation.
    • Dosing Specificity: Best efficacy is observed specifically with FOLFIRI + Bevacizumab; the combination with FOLFOX showed lower efficacy, potentially limiting regimen flexibility.
  • Management Tone on the Future:

    • High Confidence: Management expresses strong conviction in the Phase 3 plan, citing "compelling efficacy trends," "significant durability," and successful FDA alignment.
    • Strategic Optimism: Highlights the "unique opportunity" to change clinical practice in a 20-year stagnant disease area.
    • Cautious Realism: Acknowledges the study is ongoing and data is still being cleaned, but emphasizes the statistical favorability of the treatment arm across diverse patient subsets (including liver mets and multi-organ involvement).
  • Miscellaneous:

    • ORR vs. PFS Dynamics: Management notes that while Bevacizumab historically improved PFS without boosting ORR, the addition of Onvancitib is expected to drive both metrics, particularly in deep tumor shrinkage allowing for curative surgery in a subset of patients.
    • Safety Profile: Emphasizes that Onvancitib demonstrates a favorable tolerability profile with no new additive toxicities when combined with first-line chemotherapy, enabling long-term administration.
Company
CARDIFF ONCOLOGY INC
Keywords
CARDIFF ONCOLOGY INC